IBIris Barshack

Iris Barshack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iris Barshack has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-scale histology reveals localized ageing signatures in normal human colon

    by Gilad Altshuler, Coral Teper, Yoash Barak, Sarit Aviel-Ronen, Alex Loebel, Iris Barshack

    Ageing is accompanied by heterogeneous changes in tissue structure, cellular composition, and microenvironments, yet how these changes are reflected in routine human histology remains poorly understood. Here, we introduce a histology-first, multi-scale digital pathology framework to study human colon ageing using hematoxylin and eosin (H&E) whole-slide images from clinically normal colon biopsies. The framework combines pathology foundation-model patch embeddings, attention-based multiple-instance learning, cell-level morphometric profiling, and prototype-based tissue compartmentalization. We show that chronological age can be predicted from normal colon tissue using mesoscopic representations derived from pathology foundation-model patch embeddings and attention-based multiple-instance learning. Incorporating cell-type-level morpho-metric features further improves prediction and refines the spatial allocation of model attention. By integrating attention maps with prototype-defined tissue compartments, we identify localized age-associated differences within stromal, epithelial, and lymphoid mucosal niches. Finally, we show that prediction-discordant cases exhibit cellular profiles shifted toward the model-assigned age group, suggesting that some apparent model errors may reflect tissue-level age discordance beyond chronological age. Together, these findings show that routine H&E histology captures spatially localized signatures of normal human colon ageing and provides a scalable framework for linking tissue morphology with biological ageing state.

  • Open Access

    Anti-4CB1: A Novel Selective HVEM-Blocking Antibody Enhancing T-Cell and Macrophage Immunity against Solid Tumors

    by Gilli Galore-Haskel, Efrat Merhavi-Shoham, Mika Shapiro, Roni Bareli, Naama Dror, Sivan Seliktar-Ofir, Katerina Shamalov, Dorit Landstein, Adva Levy-Barda, Goni Hout-Siloni, et al.

    Immune checkpoint inhibitors have improved cancer outcomes; however, many patients fail to respond, highlighting the need for novel targets. Herpes virus entry mediator (HVEM) is an immuoregulator with both inhibitory and stimulatory functions, making it a promising therapeutic candidate. We have developed anti-4CB1, a fully human monoclonal antibody (mAb) that selectively blocks HVEM interactions with BTLA and CD160. Its activity was evaluated in vitro using human tumor-infiltrating lymphocytes, peripheral blood mononuclear cells, and M1 macrophages, as well as in ex vivo patient-derived tumor samples and in vivo transgenic and humanized mouse models. HVEM expression was also assessed in serum and tumor tissues. Anti-4CB1 enhanced T-cell activation and cytotoxicity, evidenced by increased tumor cell killing, upregulation of activation markers (41BB and CD107a), and elevated IFNγ and TNFα secretion. It also promoted macrophage-mediated phagocytosis. In ex vivo analyses of 49 patient-derived tumor samples, anti-4CB1 increased cytotoxicity in 28.5% of cases, including samples unresponsive to anti-PD1. In vivo, anti-4CB1 demonstrated significant antitumor activity as monotherapy and showed enhanced efficacy in combination with anti-PD1. Additionally, higher tumor HVEM expression correlated with improved response to checkpoint blockade, whereas elevated soluble HVEM levels were associated with reduced responsiveness to anti-HVEM. Anti-4CB1 enhances both adaptive and innate antitumor immunity and shows activity in anti-PD1–resistant settings. These findings support its potential as a novel therapeutic agent and suggest HVEM as a predictive biomarker for immunotherapy response.


  • Open Access

    Supplementary Figures and Tables from Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity

    by Lea Monteran, Nour Ershaid, Ye’ELa Scharff, Yazeed Zoabi, Tamer Sanalla, Yunfeng Ding, Anna Pavlovsky, Yael Zait, Marva Langer, Tal Caller, et al.

    Supplementary Figure 1: Bone metastasis immunosuppressive microenvironment. Supplementary Figure 2: Gating strategy for RNA sequencing. Supplementary Figure 3: Differentially expressed genes during breast cancer bone metastasis progression. Supplementary Figure 4: Metastasis-infiltrating T cells are profoundly altered by metastatic progression. Supplementary Figure 5: Immune Checkpoint Receptors (ICRs) are expressed by metastasis-infiltrating T cells. Supplementary Figure 6: Targeting TIGIT results in activation of T cell mediated anti-tumor immunity. Supplementary Figure 7: (a) Spinal Cord Compression occurrence in treated mice. P-values were calculated using two-sided Chi square test. Supplementary Figure 8: TIGIT is highly expressed in human bone metastasis. Supplementary Table 1: Patient cohort data. Supplementary Table 2: Primers sequences.

  • Open Access

    Data from Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity

    by Lea Monteran, Nour Ershaid, Ye’ELa Scharff, Yazeed Zoabi, Tamer Sanalla, Yunfeng Ding, Anna Pavlovsky, Yael Zait, Marva Langer, Tal Caller, et al.

    Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. Utilizing an immunocompetent mouse model of spontaneous breast cancer bone metastasis, we profiled the immune transcriptome of bone metastatic lesions and peripheral bone marrow at distinct metastatic stages, revealing dynamic changes during the metastatic process. We show that cross-talk between granulocytes and T cells is central to shaping an immunosuppressive microenvironment. Specifically, we identified the PD-1 and TIGIT signaling axes and the proinflammatory cytokine IL1β as central players in the interactions between granulocytes and T cells. Targeting these pathways in vivo resulted in attenuated bone metastasis and improved survival, by reactivating antitumor immunity. Analysis of patient samples revealed that TIGIT and IL1β are prominent in human bone metastasis. Our findings suggest that cotargeting immunosuppressive granulocytes and dysfunctional T cells may be a promising novel therapeutic strategy to inhibit bone metastasis.Significance:Temporal transcriptome profiling of the immune microenvironment in breast cancer bone metastasis revealed key communication pathways between dysfunctional T cells and myeloid derived suppressor cells. Cotargeting of TIGIT and IL1β inhibited bone metastasis and improved survival. Validation in patient data implicated these targets as a novel promising approach to treat human bone metastasis.


  • Open Access

    Response to Narrowband Ultraviolet B Phototherapy in Early Mycosis Fungoides Is Associated With Morphometric Histological Characteristics

    by Ilan Vashurin, Gil Goldinger, Lotan Levin, Karin Warshavsky, Felix Pavlotsky, Iris Barshack, Aviv Barzilai

    Background and Objective: Narrowband ultraviolet B phototherapy is an established treatment for mycosis fungoides. Data on the factors that predict treatment efficacy are scarce. This study evaluated the association between morphometry of histological parameters and narrowband ultraviolet B efficacy in patients with early‐stage mycosis fungoides. Patients and Methods: Morphometric analyses of the degree of spongiosis and the number and size of lymphocytes in the epidermis were conducted retrospectively on biopsies from 57 patients with early‐stage mycosis fungoides treated with narrowband ultraviolet B phototherapy. Half of the patients achieved remission after 8 weeks and half did not. Results: TCR monoclonality, larger epidermal lymphocytes, and higher degree of spongiosis were associated with poor response ( p < 0.05) with a sensitivity of 0.82, 0.93, and 0.77, respectively, and a specificity of 0.52, 0.79, and 0.72, respectively. This association was still evident at the end of the phototherapy course. Larger lymphocytes in the epidermis correlated with TCR monoclonality ( p = 0.023). Spongiosis was independent of clonality. Conclusion: Morphometric analysis of histological parameters, such as spongiosis and lymphocyte size, is associated with response to narrowband ultraviolet B phototherapy in patients with early‐stage mycosis fungoides and may serve as markers for selecting appropriate, individualized treatment plans. Incorporating morphometry into biopsy analysis of early‐stage MF may also provide better diagnostic and prognostic accuracy.

  • Abnormal immunoglobulin expression and B-cell follicle organization in inborn errors of immunity/primary immunodeficiency

    by Shachar Naor, Ginette Schiby, Etai Adam, Raz Somech, Yossef Molchanov, Iris Barshack, David B. Lewis, Lianna Marks, Dita Gratzinger

    Patients with inborn errors of immunity/primary immunodeficiency (IEI/PID) frequently present with reactive lymphadenopathy which is biopsied to rule out lymphoma or infection. We asked whether reactive lymphoid tissue from an international cohort of 35 patients with IEI/PID contains diagnostic clues to the underlying immune dysfunction as compared to 13 control pediatric patients. To this end, we investigated abnormalities of B-cell follicle architecture and Immunoglobulin G (IgG) + class-switched (CS) versus IgM/IgD + non-IgG-CS Ig production. Abnormalities of B-cell follicles including absent or naked germinal centers (GCs) and/or increased T follicular helper(TFH) cells within GCs were seen in 45.7% (16/35) of IEI/PIDs and 15.4% (2/13) of controls (X2 = 3.7520, p = 0.054). There was a statistically significant association of B-cell follicle abnormalities with infectious (X2 = 5.148, p = 0.023) but not autoimmune history. Abnormal IgM + , IgD + , IgG + and/or CD138 + plasmablast/plasma cell (PB/PC) density was observed in 79.4% of IEI/PIDs (27/34) as compared to 7.7% of controls (1/13, X2 = 20.085, p < 0.001). Isolated deficiency of IgG CS PB/PC was present in 42% (12/33) of IEI/PID biopsies and in no control patients, 0% (0/13, X2 = 6.396, p = 0.011). There was a strong and highly statistically significant positive correlation between IgG + PB/PC density and serum IgG (Kendall’s tau-b 0.567, asymptotic standard error 0.129, approximate significance < 0.001). There was also a statistically significant association of PB/PC abnormalities with infectious (X2 = 12.024, p < 0.001) but not autoimmune history. Assessment of B-cell follicle architecture and Ig production may play a role in identifying patients with unexplained reactive lymphadenopathy who would benefit from immunologic evaluation.

  • Open Access

    Table S6 from MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2

    by Ettai Markovits, Ortal Harush, Erez N. Baruch, Eldad D. Shulman, Assaf Debby, Orit Itzhaki, Liat Anafi, Artem Danilevsky, Noam Shomron, Guy Ben-Betzalel, et al.

    Differential gene expression analysis between Interferon Resistance Score (IRS) high and low tumors in four melanoma cohorts. Related to Figure 2.

  • Open Access

    Table S4 from MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2

    by Ettai Markovits, Ortal Harush, Erez N. Baruch, Eldad D. Shulman, Assaf Debby, Orit Itzhaki, Liat Anafi, Artem Danilevsky, Noam Shomron, Guy Ben-Betzalel, et al.

    Similarity between TIL ACT and PD-1 blockade response mechanism. Related to Figure S1.

  • Open Access

    Supplementary Figure Legends from MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2

    by Ettai Markovits, Ortal Harush, Erez N. Baruch, Eldad D. Shulman, Assaf Debby, Orit Itzhaki, Liat Anafi, Artem Danilevsky, Noam Shomron, Guy Ben-Betzalel, et al.

  • Open Access

    Table S5 from MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2

    by Ettai Markovits, Ortal Harush, Erez N. Baruch, Eldad D. Shulman, Assaf Debby, Orit Itzhaki, Liat Anafi, Artem Danilevsky, Noam Shomron, Guy Ben-Betzalel, et al.

    Differential gene expression analysis between responders and non-responders to immunotherapy. Related to Figure 1.